Orfadin
nitisinone
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor, pharmacist or nurse.
This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
What Orfadin is and what it is used for
What you need to know before you take Orfadin
How to take Orfadin
Possible side effects
How to store Orfadin
Contents of the pack and other information
Orfadin contains the active substance nitisinone. Orfadin is used to treat:
a rare disease called hereditary tyrosinemia type 1 in adults, adolescents and children (in any age range)
a rare disease called alkaptonuria (AKU) in adults
In these diseases your body is unable to completely break down the amino acid tyrosine (amino acids are building blocks of our proteins), forming harmful substances. These substances are accumulated in your body. Orfadin blocks the breakdown of tyrosine and the harmful substances are not formed.
For the treatment of hereditary tyrosinemia type 1, you must follow a special diet while you are taking this medicine, because tyrosine will remain in your body. This special diet is based on low tyrosine and phenylalanine (another amino acid) content.
For the treatment of AKU, your doctor may advice you to follow a special diet.
if you are allergic to nitisinone or any of the other ingredients of this medicine (listed in section 6).
Do not breast-feed while taking this medicine, see section “Pregnancy and breast-feeding”.
Talk to your doctor or pharmacist before taking Orfadin.
Your eyes will be checked by an ophthalmologist before and regularly during nitisinone treatment. If you get red eyes or any other signs of effects on the eyes, contact your doctor
immediately for an eye examination. Eye problems could be a sign of inadequate dietary control (see section 4).
During the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adequate and to make sure that there are no possible side effects causing blood disorders.
If you receive Orfadin for treatment of hereditary tyrosinemia type 1, your liver will be checked at regular intervals because the disease affects the liver.
Follow-up by your doctor should be performed every 6 months. If you experience any side effects, shorter intervals are recommended.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Orfadin may interfere with the effect of other medicines, such as:
Medicines for epilepsy (such as phenytoin)
Medicines against blood clotting (such as warfarin)
If you start treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment.
The safety of this medicine has not been studied in pregnant and breast-feeding women.
Please contact your doctor if you plan to become pregnant. If you become pregnant you should contact your doctor immediately.
Do not breast-feed while taking this medicine, see section “Do not take Orfadin”.
This medicine has minor influence on the ability to drive and use machines. However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4“Possible side effects”).
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
For hereditary tyrosinemia type 1, treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease.
For hereditary tyrosinemia type 1, the recommended total daily dose is 1 mg/kg body weight administered orally. Your doctor will adjust the dose individually.
It is recommended to administer the dose once daily. However, due to the limited data in patients with body weight <20 kg, it is recommended to divide the total daily dose into two daily administrations in
this patient population.
For AKU, the recommended dose is 10 mg once daily.
If you have problems with swallowing the capsules, you may open the capsule and mix the powder with a small amount of water or formula diet just before you take it.
If you have taken more of this medicine than you should, contact your doctor or pharmacist as soon as possible.
Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, contact your doctor or pharmacist.
If you have the impression that the medicine is not working properly, talk to your doctor. Do not change the dose or stop the treatment without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any side effects relating to the eyes, talk to your doctor immediately to have an eye examination. Treatment with nitisinone leads to higher levels of tyrosine in the blood which can cause eye related symptoms. In patients with hereditary tyrosinemia type 1, commonly reported eye related side effects (may affect more than 1 in 100 people) caused by higher tyrosine levels are inflammation in the eye (conjunctivitis), opacity and inflammation in the cornea (keratitis), sensitivity to light (photophobia) and eye pain. Inflammation of the eyelid (blepharitis) is an uncommon side effect (may affect up to 1 in 100 people).
In AKU patients, eye irritation (keratopathy) and eye pain are very commonly reported side effects (may affect more than 1 in 10 people).
Other common side effects
Reduced number of platelets (thrombocytopenia) and white blood cells (leukopenia), shortage of certain white blood cells (granulocytopenia).
Other uncommon side effects
increased number of white blood cells (leucocytosis),
itching (pruritus), skin inflammation (exfoliative dermatitis), rash.
Other common side effects
bronchitis
pneumonia
itching (pruritus), rash
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting
system listed in Appendix V. By reporting side effects you can help provide more information on the
safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and the carton after “EXP”. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C).
The medicine can be stored for a single period of 2 months (for 2 mg capsules) or 3 months (for 5 mg, 10 mg and 20 mg capsules) at a temperature not above 25°C, after which it must be discarded.
Do not forget to mark the date on the bottle, when removed from the refrigerator.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is nitisinone.
Orfadin 2 mg: Each capsule contains 2 mg nitisinone.
Orfadin 5 mg: Each capsule contains 5 mg nitisinone. Orfadin 10 mg: Each capsule contains 10 mg nitisinone. Orfadin 20 mg: Each capsule contains 20 mg nitisinone.
The other ingredients are Capsule content:
starch, pregelatinised (maize). Capsule shell:
gelatine
titanium dioxide (E 171). Printing ink:
iron oxide (E 172)
shellac propylene glycol
ammonium hydroxide
The hard capsules are white, opaque, imprinted with “NTBC” and the strength “2 mg”, “5 mg”, “10 mg” or “20 mg”, in black. The capsule contains a white to off-white powder.
The capsules are packaged in plastic bottles with tamper-proof closures. Each bottle contains 60 capsules.
Swedish Orphan Biovitrum International AB SE-112 76 Stockholm
Sweden
Apotek Produktion & Laboratorier AB Prismavägen 2
SE-141 75 Kungens Kurva
Sweden
. There are also links to other websites about rare diseases and treatments.